(Q28589203)

31 January 2017

title

Docosahexaenoic acid deficit is not a major pathogenic factor in peroxisome-deficient mice (English)

1 reference

Peroxisomal biogenesis factor 5

31 January 2017

main subject

1 reference

GOA release 2020-03-11

author name string

A. Janssen

1

1 reference

31 January 2017

M. Baes

2

1 reference

31 January 2017

P. Gressens

3

1 reference

31 January 2017

G. P. Mannaerts

4

1 reference

31 January 2017

P. Declercq

5

1 reference

31 January 2017

P. P. Van Veldhoven

6

1 reference

31 January 2017

publication date

1 January 2000

1 reference

31 January 2017

published in

Laboratory Investigation

1 reference

31 January 2017

volume

80

1 reference

31 January 2017

issue

1

1 reference

31 January 2017

page(s)

31–35

1 reference

A mouse model for Zellweger syndrome

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Targeted Deletion of the PEX2 Peroxisome Assembly Gene in Mice Provides a Model for Zellweger Syndrome, a Human Neuronal Migration Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Mechanisms of docosahexaenoic acid accretion in the fetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Fatty acid composition of late embryonic and early postnatal rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Docosahexaenoic acid--a new therapeutic approach to peroxisomal-disorder patients: experience with two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Tissue levels of polyunsaturated fatty acids during early human development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Peroxisomal lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Lipids of nervous tissue: composition and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

Membrane docosahexaenoate is supplied to the developing brain and retina by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

A method for the quantitative determination of glycerolipids containing O-alkyl and O-alk-1-enyl moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

7 January 2021

Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

7 January 2021

Trial of docosahexaenoic acid supplementation on a Japanese patient with a peroxisome biogenesis defect

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

7 January 2021

Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3780005

7 January 2021

10.1038/LABINVEST.3780005

Identifiers

DOI

0 references

Dimensions Publication ID

1042993174

0 references

1 reference